Trial Profile
A Phase 3 Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) as First-line Therapy in Participants With Advanced Merkel Cell Carcinoma (KEYNOTE-913)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Mar 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Merkel cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-913
- Sponsors Merck Sharp & Dohme Corp.
- 23 Feb 2024 Status changed from active, no longer recruiting to completed.
- 07 Dec 2023 Planned End Date changed from 16 Jun 2032 to 15 Feb 2024.
- 07 Sep 2021 Planned primary completion date changed from 13 Sep 2021 to 15 Feb 2022.